Disc Medicine, Inc.
Hematology-focused biotech developing therapies that modulate heme biosynthesis and iron homeostasis, led by bitopertin in EPP.
Hematology / rare blood disorders · Small molecules & monoclonal antibodies targeting heme/iron biology · Phase 3 / CRL response planned by end 2026